Memory Pharmaceuticals Corporation

Other

Memory Pharmaceutical Corporation

F. Hoffmann-la Roche Ag

Allen T Hopper

Ashok Tehim

Hans-Jurgen E Hess

Francisco Xavier Talamas

Richard A Schumacher

Sharada Shenvi Labadie

Ruiping Liu

Erik Mikal Kuester

Robert F Dunn

Richard Conticello

Wenge Xie

Brian Herbert

Truc Minh Nguyen

Axel Unterbeck

William F Brubaker

Michael De Vivo

Yajing Rong

Elizabeth Doorly Graham

Ian Egle

Shawn Maddaford

William J Delaney

Thomas E Renau

William Frederick Brubaker, Jr

Mike De Vivo

Hans-Jürgen Ernst Hess

Hans-J&uuml;rgen Ernst Hess

Zhaoqing Wang

Mark Phillip Arrington

The compounds of the present invention are of formula I: wherein A, R, Ris as defined herein, are useful as ligands for nicotinic receptors.

Heterocyclic compounds, methods for the preparation thereof, and uses thereof

Selective PDE4 inhibition is achieved by aryl and heteroaryl pyrazole compounds. The compounds exhibit improved PDE4 inhibition as compared to compounds such as rolipram and show selectivity with regard to inhibition of other classes of PDEs.

Phosphodiesterase 4 inhibitors

PDE4 inhibition is achieved by novel nitroxide compounds, e.g., N-substituted aniline and diphenylamine analogs. The compounds of the present invention are of Formulas I-III: wherein A, B, D, R, R, R, R, R, R, Rand Rare as defined herein.

Selective PDE4 inhibition is achieved by 4-(substituted-phenyl)-2-pyrrolidinone compounds. The compounds exhibit improved PDE4 inhibition as compared to compounds like rolipram and show selectivity with regard to inhibition of other classes of PDEs. The compounds of the present invention are of formula I: wherein R, R, and Rare as defined herein.

PDE4 inhibition is achieved by novel compounds, e.g., aminoindazole and aminobenzofuran analogs. The compounds of the present invention are of Formulas I and II: wherein R, R, R, R, Rand Rare as defined herein.

Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs

Selective PDE4 inhibition is achieved by novel compounds, e.g., 4-(substituted-phenyl)-2-pyrrolidinone compounds. The compounds of the present invention are of formula I: wherein R, R, and Rare as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

Certain thienopyrimidine derivatives are useful for the inhibition of PDE10 enzymes, and thus are useful for treating psychiatric or neurological syndromes, e.g., pyschoses, obsessive-compulsive disorder and/or Parkinson's disease, as well as, for example, treating a disease state modulated by PDE10 activity.

Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors

PDE4 inhibition is achieved by novel compounds, e.g., N-substituted aniline and diphenylamine analogs. The compounds of the present invention are of Formula I: wherein R, R, Rand Rare as defined herein.

Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs

PDE4 inhibition is achieved by novel compounds of the Formula I: wherein Rand Rare as defined herein.

The compounds of the present invention are of formula I:wherein A, R, Ris as defined herein, are useful as ligands for nicotinic receptors.

Growing community of inventors

Glen Rock, NJ, United States of America

Allen T Hopper